Pharmacotherapeutic considerations in anesthesia.
This article focuses on new findings leading to improved understanding of the pathophysiology and mechanisms of potential drug interactions between anesthetic drugs or techniques and cardiovascular medications in patients scheduled for surgery. Only the most frequently used drugs are reviewed. Elective surgery provides the luxury to consider these risks and alter therapy accordingly. Under urgent circumstances, however, the increased risks associated with these agents should be anticipated with the goal to minimize adverse effects while maintaining optimal cardiovascular function in the perioperative period.
Goldstein
Sheldon
S
Division of Cardiac Anesthesia, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Amar
David
D
D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D000758:Anesthesia; D000777:Anesthetics; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000933:Antifibrinolytic Agents; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D004232:Diuretics; D004347:Drug Interactions; D006801:Humans; D010975:Platelet Aggregation Inhibitors
D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D000777:Anesthetics; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000933:Antifibrinolytic Agents; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D004232:Diuretics; D010975:Platelet Aggregation Inhibitors